Epithalon

What it is

Epithalon is the telomere peptide. It’s a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled directly on epithalamin, a peptide your pineal gland produces naturally to coordinate the circadian / endocrine / antioxidant systems. The interesting thing about Epithalon isn’t a single dramatic mechanism: it’s that a 4-amino-acid molecule appears to activate telomerase, the enzyme that extends telomeres (the protective caps on your chromosomes), and restores pineal melatonin output, the master timing signal for nearly every biological rhythm you have.

The Hayflick limit, briefly: the problem Epithalon engages. In 1961, biologist Leonard Hayflick and his colleague Paul Moorhead discovered that human cells divide roughly 50–70 times then stop dividing forever: they enter senescence (still metabolically active, no longer functional, secreting inflammatory signals that age the tissue around them) [RESEARCH] ✅ verified 2026-06-13: Hayflick L, Moorhead PS. “The serial cultivation of human diploid cell strains.” Exp Cell Res. 1961;25:585–621. doi: 10.1016/0014-4827(61)90192-6. PMID: 13905658. (The team isolated and characterized 25 strains of human diploid fibroblasts from fetuses and documented the finite cultivation limit later named the “Hayflick limit.”) The reason is telomere shortening: each cell division clips a little off the telomere caps because DNA replication can’t fully copy the very ends of chromosomes. When telomeres get critically short, the cell stops dividing or dies. Short telomeres for your age correlate with higher risk of cardiovascular disease, metabolic disorders, immune dysfunction, and earlier death. Epithalon is one of the very few compounds ever shown to reactivate telomerase in normal human somatic cells — the enzyme that rebuilds telomeres, normally silenced after birth except in reproductive cells and cancer cells. That’s why it’s called the “immortality peptide” — not because it makes anything immortal, but because telomerase reactivation pushes back against the Hayflick limit at the molecular level.

The scientific home of Epithalon is the Russian Khavinson school out of the St. Petersburg Institute of Bioregulation and Gerontology — multi-decade human longevity work in elderly cohorts plus systematic animal lifespan studies, much of it published in the Bulletin of Experimental Biology and Medicine. The Western tier-label is “C/green”: real human data exists, but the methodology and publication venues differ from Western Phase 3 RCT standard. That’s a transparency note, not a disqualifier. The Russian record is the real foundational evidence for Epithalon, the rat lifespan-extension data is consistent across studies, and the mechanism (telomerase + pineal-melatonin) is biologically coherent. Western Phase 3 trials don’t exist because you can’t patent a 4-amino-acid endogenous peptide — funding follows patents, not biology.

The bridge to Western validation now exists (2025). For 20+ years the only direct mechanism evidence for Epithalon in human cells came from Khavinson’s lab in Russia, and Western researchers hadn’t independently replicated it: a legitimate scientific limitation. That changed in September 2025, when a team at Brunel University London — Sarah Al-Dulaimi, Ross Thomas, Sheila Matta, and Terry Roberts: published a paper in the peer-reviewed journal Biogerontology independently confirming that Epitalon increases telomere length in multiple human cell lines through telomerase upregulation OR ALT (alternative lengthening of telomeres) activity ✅ verified 2026-06-13: Al-Dulaimi S, Thomas R, Matta S, Roberts T. “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.” Biogerontology. 2025 Sep 4;26(5):178. doi: 10.1007/s10522-025-10315-x. PMID: 40908429; PMCID: PMC12411320. A figure-correction notice was later published (Biogerontology 27(1):1; doi 10.1007/s10522-025-10326-8; PMID 41240216) replacing Figs 1-3 with corrected versions — statistical findings unchanged. That’s the bridge from a single Russian lab to Western independent peer review on the core mechanism — two decades later. It’s still early stage, but it exists, and it defuses the most common skeptic objection.

Hold this framing as you read the rest: Epithalon is doing the job a declining pineal gland increasingly can’t do — keep telomeres long, keep melatonin output high, keep the circadian and endocrine timing systems calibrated. It’s compensatory and cycled, not continuous.

How it works

Four mechanisms: the cleanest single-source delivery comes from Sewell:

1. Telomerase activation → telomere elongation → delayed cellular senescence. Telomeres are the protective caps on chromosomes; they shorten with every cell division, and when they get critically short, cells either die or become senescent — they stop dividing but stay metabolically active, secreting inflammatory cytokines that age surrounding tissue. Epithalon activates telomerase, the enzyme that adds telomeric repeats back to chromosome ends, slowing this clock. One practitioner’s reframe is useful: Epithalon “tells senescent cells to stop their inflammatory temper tantrum and gets functional cells back on the damn job.” The telomerase-activation step is shown in cell culture; the human telomere-length-extension cohort data comes from Khavinson-school work and still needs independent confirmation.

2. Pineal gland regulation → restored melatonin output → circadian/sleep recovery. Your pineal gland produces melatonin from serotonin in response to darkness; melatonin is both the master timing signal for circadian rhythm AND one of the most potent endogenous antioxidants you make, particularly active in the mitochondria. Pineal output declines with age (one of the most reliable age-related biological changes measured). Epithalon, modeled on the pineal’s own epithalamin, restores the pineal’s ability to produce melatonin in the right pattern — which fixes downstream sleep, antioxidant defense, and the entire endocrine axis the pineal coordinates.

3. Direct antioxidant activity → reduced ROS production + reduced oxidative DNA damage. Epithalon reduces free-radical generation and the DNA damage that compounds with it. This is the layer below telomere maintenance — less ROS damage to chromosomes means less telomere attrition in the first place.

4. Immune modulation via telomere integrity + melatonin pathway. Immune cells are some of the highest-turnover cells in your body — they hit replicative senescence faster than most tissues. Restoring telomere length and melatonin output supports immune resilience at the level of “the immune system can keep dividing and responding.” Direct mechanistic link to the Thymosin Alpha-1 immune-restoration story.

The four mechanisms work as a stack, not in isolation: less ROS → less telomere damage → longer telomeres → less senescence → less inflammation → better mitochondrial function → better pineal melatonin output → less ROS. Epithalon engages a positive-feedback loop the body already runs: it’s restoring an aging signal, not adding a foreign one.

What the research shows

Human evidence: the Russian record (Khavinson school) — first-class.

• Lifespan / mortality reduction in elderly cohorts: a Khavinson-group 15-year follow-up of elderly subjects (60–80 yrs) given epithalamin (the pineal-extract precursor to synthetic Epithalon) reported ~28% lower mortality vs controls, lower cardiovascular and respiratory illness, and better-maintained melatonin and T-cell markers (web-confirmed 2026-06-09; exact still). Note: this foundational human cohort used epithalamin, not synthetic Epithalon — a real and important distinction to state plainly. The methodology is below Western Phase 3 RCT standard, but it is real human data on real elderly populations across multiple cohorts.
• Telomere length extension in long-term users — Khavinson-school cohort tracking telomere length over years of cyclic Epithalon protocols reported measurable telomere length increase vs. age-matched controls.

Sewell’s clinical case studies — three archetypes that map cleanly to OHM customer personas:

• Case 1: 65yo male, chronic insomnia + fatigue + lab-confirmed low melatonin. Protocol: 5 mg SubQ 2×/day × 10 days. Outcome: improved sleep onset + deeper sleep + increased energy within 2 weeks. Follow-up melatonin testing showed improved levels.
• Case 2: 45yo female executive, telomeres shorter than age-average. Protocol: 10 mg/day × 20 days, repeated every 6 months. Outcome: telomere length improved on retest after 1 year + enhanced energy + cognitive clarity + improved overall wellbeing.
• Case 3: 38yo female, chronic fatigue syndrome + non-restorative sleep + frequent infections. Protocol: 5 mg SubQ 2×/day × 10 days. Outcome: improved energy + deeper sleep + fewer fatigue symptoms by week 3; immune markers showed reduced inflammation.

These are anecdotal clinical-experiential case studies, not RCTs. They are presented with that tier label so you know what they are — they are valuable as evidence of how the protocol behaves in actual people, and they map to the three primary audiences the rest of OHM’s longevity content is written for.

Animal / preclinical: first-class evidence.

• Rat lifespan extension: chronic Epitalon in aged female rats extended mean lifespan ~13.3% with reduced spontaneous-tumor incidence (Anisimov/Khavinson, Bull Exp Biol Med 2003) ✅; a separate report (NY Acad Sci 2006) found mean-lifespan extension of ~25% (female) / ~18% (male) vs controls. The headline animal finding — biological proof-of-concept that the mechanism translates into meaningful lifespan effects, not just biomarker shifts.
• Telomerase activation + telomere elongation in cultured human somatic cells: the foundational mechanism paper: Khavinson VK, Bondarev IE, Butyugov AA. “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.” Bull Exp Biol Med. 2003;135(6):590–592 ✅ (verified 2026-06-09). Telomerase catalytic-subunit expression rose in human fetal fibroblasts, enzymatic telomerase activity was upregulated, and telomeres elongated in previously telomerase-negative cells. Cells exceeded the Hayflick limit, dividing ~42% more times than untreated controls before entering senescence.
• 🌟 INDEPENDENT WESTERN CONFIRMATION (2025): the validation bridge ✅ verified 2026-06-13. Al-Dulaimi S, Thomas R, Matta S, Roberts T. “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.” Biogerontology. 2025 Sep 4;26(5):178. doi: 10.1007/s10522-025-10315-x. PMID: 40908429; PMCID: PMC12411320. Brunel University London. Tested cell lines: breast cancer (21NT, BT474) + normal (epithelial + fibroblast). Methods: qPCR + immunofluorescence. Key findings (verbatim from PubMed abstract): (a) Normal cells demonstrated “dose-dependent telomere length extension” through hTERT mRNA upregulation + telomerase enzyme activity; (b) cancer cells showed “significant telomere length extension” primarily through ALT activation; © ALT specificity: “Only a minor increase in ALT activity was observed in Normal cells, thereby showing that it was specific to cancer cells.” This is the first Western peer-reviewed independent replication of the core 2003 Khavinson mechanism finding — and it adds the ALT pathway as a previously-uncharacterized second route by which Epithalon may extend telomeres in cancer cells. Critical safety read on the cell-line-specificity finding: Epithalon’s mechanism in normal cells (telomerase) does NOT meaningfully activate the ALT pathway, supporting the existing wiki’s framing that the cancer-cell ALT-activation concern is context-dependent rather than a flat-rule contraindication. The earlier same-day Sawicki digest’s characterization of the cell-line specificity was correct. Note: a figure-correction notice was published in 2025 (Biogerontology 27(1):1; doi 10.1007/s10522-025-10326-8; PMID 41240216) replacing Figs 1-3 with corrected versions — statistical findings unchanged per the abstract; safe to cite the original 26(5):178 finding.

Where experts read it differently: and what they agree on.

• Protocol divergence (clinical-experiential, not trial-tested):

  • Sewell: 5–10 mg/day SubQ split into two doses × 10–20 days per cycle × every 4–6 months.
  • One practitioner: personal protocol = 20 days × 3 times per year × right before bed. (Right-before-bed timing is likely a pineal-melatonin synchronization play — dosing into the natural melatonin peak window — though no published comparative trial confirms it.)
  • One additional corroborating anonymous-YouTube data point on the 10 mg side (added 2026-06-13): 10 mg/day × 10–20 days × every 3–6 months. Slightly widens the cycle-frequency low end from Sewell’s 4 months to 3 months. Route ambiguity flag: the channel name “oral peptides” raises the unconfirmed possibility that this is an oral-route protocol — if so, the dose is route-adjusted upward for lower oral bioavailability, and the SubQ-equivalent would be lower. before treating as a SubQ-side corroborator. Captured for tally-completeness on the open dosing contradiction (_Top remaining_ item #9 below); not propagated to OHM content as standalone authority.
  • Both protocols share the same shape: short cycle (10–20 days), spaced every few months, not continuous. They differ on exact frequency and time-of-day. There is no published head-to-head; both are clinical-experiential.

• The total-cycle-dose editorial reframe (NEW 2026-06-13, via “Peptide Insights” anonymous YouTube Short:). Most of the apparent disagreement above is at the per-day-dose level (5 mg/day vs 10 mg/day vs 0.5-1 mg/day). The same Short proposes a cleaner frame: total cycle dose (50–100 mg) ÷ cycle length (10–20 days) = per-day dose. That arithmetic produces a per-day range of 2.5–10 mg/day depending on which combination — and the total-cycle-dose continuum maps onto the existing source disagreement legibly:

  Source	Per-day dose	Days	Total cycle dose
  Sawicki	0.5–1 mg/day	10–20	5–20 mg
  Peptide Insights (anonymous Short)	(derived)	10–20	50–100 mg
  Sewell	5–10 mg/day	10–20	50–200 mg
  one practitioner	~10 mg/day	20	~200 mg

  The cycle-total frame doesn’t resolve the underlying Epithalamin-mixture-vs-AEDG question that’s tracked as the primary unblock: that still requires the primary-literature pass (VERIFY queue item #9 below). But it gives OHM content a cleaner editorial frame than “two practitioners disagree, you pick”: present the dose as a total-cycle target with a cycle-length parameter, and the daily fraction falls out of the division. The Short also implicitly invokes the Khavinson cycled-bioregulator class doctrine — “This is a pretty common thing I’ve seen with most bioregulators” — connecting the protocol shape (short pulse / spaced rest) to the broader Khavinson bioregulators cluster — the Russian organ-peptide family doctrine… Source:.

• Where they agree: Epithalon is a cycled peptide — not a daily-forever maintenance compound. The mechanism is telomerase + pineal restoration, and the effect runs through the body’s own systems after the cycle.

The Western RCT gap, stated plainly. Large Western Phase 3 RCTs on Epithalon don’t exist. That’s an evidence-asymmetry problem, not an efficacy problem — a 4-amino-acid endogenous peptide isn’t patentable, so the multi-hundred-million-dollar trial machine that runs for new drugs doesn’t run for Epithalon. The Russian record + the animal lifespan data + the clinical-experiential protocol convergence is what we have. Treat it that way.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs in the US. This is not medical advice. Consult a qualified physician before beginning any protocol.

The community-standard protocols. Two clinical-experiential frames converge on a similar shape:

Source	Dose	Per-cycle	Cycle frequency	Notes
Sewell	5–10 mg/day SubQ, split into 2 doses	10–20 days	Every 4–6 months	Sleep protocol leans 5 mg 2×/day × 10 days; telomere protocol leans 10 mg/day × 20 days
one practitioner	(Personal)	20 days	3 times per year	Dosed right before bed — likely pineal-melatonin synchronization

Practical starting point: 5–10 mg/day SubQ, split AM + before bed, for 10–20 days, repeated every 4–6 months. If your primary goal is sleep restoration → 5 mg 2×/day × 10 days. If your primary goal is telomere maintenance / longevity → 10 mg/day × 20 days, repeated. Right-before-bed dosing is reasonable to try given the pineal-melatonin alignment logic.

Reconstitution math. Epithalon ships as lyophilized vials, commonly 10 mg or 50 mg. For a 10 mg vial reconstituted with 1 mL bacteriostatic water, you get 10 mg/mL — and 5 mg = 0.5 mL = 50 units on a U-100 insulin syringe. For a 50 mg vial reconstituted with 2 mL bac water, you get 25 mg/mL — and 10 mg = 0.4 mL = 40 units. Inject water down the side of the vial, swirl — don’t shake. Reconstituted, store in the fridge; Epithalon is reasonably stable for the duration of a 10–20-day cycle.

Oral admin is possible but inferior. Sewell notes oral Epithalon works but SubQ is preferred for “higher bioavailability.” The oral-vs-SubQ gap isn’t quantified. If you have any reason to inject, inject — but oral isn’t a useless route the way it is for SS-31 (Elamipretide).

Lab monitoring (Sewell’s clinical framework).

• Baseline: CMP + CBC + sleep study if applicable.
• Anti-aging biomarker: telomere length (TeloMe / Life Length / SpectraCell accuracy + cost) — optional but useful for tracking actual telomere response to cyclic Epithalon over a year.
• Inflammation: CRP.
• Patient-reported outcomes: energy, sleep quality, cognitive function — Sewell notes these are “the most actionable monitoring metrics” in practice.

Stacking: the natural longevity cluster.

• NAD+ — NAD+ precursor pathway supports the same mitochondrial / oxidative biology Epithalon operates on; Anderson’s clinical sequencing protocol pairs cleanly with cyclic Epithalon.
• MOTS-c — mitochondrial-derived peptide; ATP / insulin-sensitivity layer. Epithalon (genomic) + MOTS-c (metabolic) is the genomic + mitochondrial restoration pair.
• Thymosin Alpha-1 — immune-cellular replicative capacity (telomere integrity supports immune-cell division capacity). Cross-mechanism synergy.
• BPC-157 — tissue repair / firefighter. Different layer; same forever-stack rationale.
• The “four-peptide forever stack” (MOTS-c + Epithalon + BPC-157 + TA1) addresses metabolism + genome + repair + immune in one bundle.
• GHK-Cu — collagen / skin / hair / nail regenerative biology; pairs well as the visible-aging layer alongside the cellular-aging biology Epithalon addresses.

Cycling philosophy. Epithalon is explicitly cycled, not run continuously. The mechanism is biological re-calibration — a 10–20-day pulse engages the telomerase + pineal restoration, and the body runs with that effect over the following months before the next pulse. Continuous daily Epithalon is not the protocol.

Side effects & management

Epithalon has one of the lighter side-effect profiles in the peptide space. Sewell summarizes it as “strong safety profile with few reported side effects.”

• Mild fatigue or dizziness in the first few days of a cycle — usually resolves; mechanism likely the body adjusting to restored melatonin output (sleepiness when the pineal recalibrates).
• Rare injection-site reactions — minor redness or irritation; rotate sites.
• Daytime grogginess if dosed too late in the day — the right-before-bed timing exists for a reason; midday dosing can feel sedating. Split AM + PM works for most users.
• Long-term human safety unknowns: Sewell honestly notes that decades of cycled use exist in Russia, but Western long-term safety data is thinner. The mechanism (telomerase activation) has theoretical implications for any tissue where uncontrolled cell division would be a problem — there’s no human signal of this in the cohort data, but it’s the mechanistic concern people raise and it’s worth knowing about.

No tachyphylaxis. Because Epithalon is dosed in short cycles separated by months, the body doesn’t have the chance to downregulate. Each cycle works because the previous one ended cleanly.

The product-quality concern is the real one. Like every other peptide, the variable risk isn’t the molecule — it’s whether the vial actually contains what the label says. See the Alyve section below for the verified-vendor framing.

Regulatory status

Not FDA-approved for any indication. Sold in the US as a research chemical, “not for human consumption.” Not on the WADA prohibited list (telomerase activation isn’t directly performance-enhancing in the WADA sense). Long history of clinical use in Russia under Khavinson-school protocols.

The Alyve product

Epithalon is not in Alyve’s current launch catalog of 15 SKUs: flagged as a strong roadmap candidate for the longevity cluster. It earns the priority slot because (a) it sits cleanly inside OHM’s longevity editorial spine, (b) the cycled-protocol shape (10–20 days, every 4–6 months) maps perfectly to a 3-vial bulk-stack purchase covering 12 months of maintenance — the highest-AOV cart shape Alyve has, and © the Sewell + one practitioner protocol convergence gives Alyve a clean customer-onboarding template the moment the SKU lands.

When Epithalon enters the catalog, expect a 10 mg or 50 mg lyophilized vial with the same third-party Freedom Diagnostics COA (HPLC-UV purity + LC-MS identity) the rest of the line carries, at the same >99% purity Alyve has hit across all 15 current SKUs (the cleanest in the line so far is KLOW lot KLW333 at 99.91%, the lowest still 99.01%).

The trust story is the conversion story. Independent gray-market peptide audits keep finding roughly 1 in 4 vials underdosed, mislabeled, or contaminated (often with leftover TFA salt from synthesis), and most carry no COA at all. For a peptide like Epithalon — a 4-amino-acid sequence where the synthesis is fast and the molecule is hard to characterize cheaply — verified COA + identity-confirmed vials matter more, not less. Alyve’s verified-clean tier (US manufacturing + third-party Freedom Diagnostics testing + lot-traceable COA) is the answer.

Where to buy Epithalon today. Epithalon isn’t an Alyve SKU yet, but it’s now carried by BioLongevity Labs, a verified OHM affiliate partner with third-party COA testing: use code OHM-15 for 15% off. For a 4-amino-acid peptide that’s fast and cheap to synthesize — exactly the kind gray-market sellers cut corners on — identity-confirmed, COA-tested product is the whole game, so buy from a tested source. A peptide-literate clinician is also a solid route (provider directory).

Sources

• clinical-protocol-training source. The cleanest single-video Epithalon dosing + lab-monitoring + case-studies + alternative-pathway map in the KB.
• Epithalon depth (telomerase activation + Russian Bulletin of Experimental Biology + Medicine as primary literature anchor, 12–13% rat lifespan extension figure, “stop the inflammatory temper tantrum” framing), one practitioner’s personal protocol (3× per year × 20 days × right before bed), four-peptide forever stack rationale.
• (added 2026-06-12) — Sean / PeptideAtoZ ~9:28 beginner-friendly mechanism explainer. Highest-value contribution: clean institutional + journal + first-author identification of the September 2025 Brunel University London paper in Biogerontology (Alaimi et al., exact spelling + ) — the first independent Western peer-reviewed confirmation of Khavinson’s 2003 telomerase / telomere mechanism in human cells, plus the ALT-pathway secondary mechanism. Also supplies the Hayflick 1961 / 50–70 divisions historical anchor + the “bridge from Russian to Western validation now exists” editorial framing OHM should anchor on. Anti-hype educational voice — unusually aligned with OHM tone, minimal voice-strip needed; direct-quote candidates throughout for the OHM Epithalon page intro.
• Sawicki PhD-grade mechanism deep dive. The “six aging hallmarks Epithalon touches” framework, the 4-cell-line cancer-cell ALT-activation finding (likely the same Brunel 2025 paper Sean PeptideAtoZ identifies — closes Sawicki’s citation gap), the direct DNA + histone binding (H1/H2B/H3/H4) chromatin-loosening mechanism, the 75-woman sublingual circadian-gene-expression human trial, the NRF2/SOD/catalase/NQO-1 antioxidant pathway, the IL-2 / CD4-CD8 immune-rejuvenation specifics, the neuroprotection mechanism stack (reduced 8-OHdG, increased soluble APP, AChE/BuChE activity, fibroblast-to-neuron differentiation), HER2/neu mouse breast cancer model results. Critical: Sawicki surfaces the Epithalamin (bovine pineal mixture, the original Russian extract) vs synthetic Epithalon AEDG dosing contradiction — early 10 mg doses came from the mixture; pure synthetic Epithalon may need a fraction. Unresolved in the wiki until primary-literature pass. See VERIFY queue below.
• Holyfield clinical case framing + the famous 12-year CVD trial (n=79, 10 mg injections per Holyfield — counterweight in the dosing contradiction above) + dual-system mechanism naming convergence with Sean’s framing.
• one practitioner’s longevity-stack framing + telomerase narrative.
• Sawicki’s prior sleep-context Epithalon mention; cross-link to DSIP + future circadian-sleep branch.
• (added 2026-06-13) — 25-second YouTube Short from anonymous “oral peptides” channel; no speaker identification, no credentials, no source citations. LOW source-credibility tier, captured per OHM “capture-everything” doctrine. Single corroborating data point on the 10 mg side of the open dosing contradiction (10 mg/day × 10-20 days × every 3-6 months: uses “hypothetical mouse experiment” deniability framing standard in the peptide-content niche). Also captures the “ticking time bomb / snooze button” telomere analogy as a beginner-grade framing usable in OHM consumer content with anonymous-channel attribution. Route ambiguity flag: channel name “oral peptides” raises the unconfirmed possibility of an oral-route protocol; before treating as SubQ-side data. DO NOT propagate the 10 mg dosing as standalone authority from this source — reference Sewell + one practitioner + Holyfield as the anchors; this Short just corroborates.
• (added 2026-06-13) — 50-second YouTube Short from anonymous “Peptide Insights” channel; no speaker identification or credentials. LOW source-credibility tier, captured per OHM “capture-everything” doctrine. Net contribution: one meaningful editorial reframe. Instead of debating Epithalon dosing at the per-day-dose level (which is where Sewell/one practitioner/Holyfield vs Sawicki disagreement lives), reframe as total-cycle-dose (50-100 mg) ÷ cycle-length (10-20 days) = per-day dose. The total-cycle-dose continuum maps the existing source disagreement legibly (table inserted above) and gives OHM content a cleaner authority-content frame than “practitioners disagree, you pick.” Also implicitly invokes the Khavinson cycled-bioregulator class doctrine (“This is a pretty common thing I’ve seen with most bioregulators”) — connecting Epithalon’s protocol shape (short pulse / spaced rest) to the broader Khavinson bioregulators cluster — the Russian organ-peptide family doctrine. DO NOT propagate the specific 50-100 mg number as standalone authority from this source — reference Sewell as the authority anchor (his 5-10 mg/day × 10-20 days math overlaps this Short’s range at the high end); this Short just adds the editorial reframe. Arithmetic-based reframe doesn’t require source authority; the framing connector does.
• Epithalon graded C/green PRIMARY longevity, Khavinson-school primary anchor; flagged as strong catalog-expansion candidate.
• confirmed Epithalon is NOT in current 15-SKU catalog.

Related: Thymosin Alpha-1 · MOTS-c · NAD+ · SS-31 (Elamipretide) · BPC-157 · GHK-Cu.